Functional analysis of individual cells and microenvironment of breast cancer-draining lymph nodes

Cancer Science

Volumn 99, Issue 5, 2008, Pages 936-945

  Zurgil, Naomi ^a   Deutsch, Assaf ^a   Afrimzon, Elena ^a   Shafran, Yana ^a   Tirosh, Reuven ^a   Sandbank, Judith ^b   Pappo, Itzhak ^b   Deutsch, Mordechai ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; TRANSFERRIN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST EXAMINATION; CANCER INVASION; CELL FUNCTION; CELL STRUCTURE; CELL SUSPENSION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LYMPH NODE CELL; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MICROENVIRONMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; BREAST TUMOR; FEMALE; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASES; MIDDLE AGED;

EID: 43649089043     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00783.x     Document Type: Article

References (34)

1. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 5th edn. Philadelphia: Lippincott, 1997.
2. Harris JR. Staging of breast carcinoma. In: Harris JR, Lippman ME, Morrow M, Wellman S, eds. Diseases of the Breast. New York: Lippincott-Raven, 1996 pp. 457-9.
3. Turner RR, Ollila DW, Krasne DL, Giuliano AL. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997; 226: 271-6.
4. Leers MPG, Schoffelen RHMG, Hoop JGM et al. Multiparameter flow cytometry as a tool for the detection of micrometastatic tumour cells in the sentinel lymph node procedure of patients with breast cancer. Clin Path 2002; 55: 359-66.
5. Pargaonkar AS, Beissner RS, Snyder S, Speights VO. Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer. Arch Pathol Lab Med 2003; 127: 701-5.
6. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: Reviewing the dilemma. Cancer 1997; 80: 1188-97.
7. Alam SM, Clark JS, George WD, Campbell AM. Altered lymphocyte populations in tumour invaded nodes of breast cancer patients. Immunol Lett 1993; 35: 229-34.
8. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992; 12: 1-12.
9. Deutsch M, Deutsch A, Shirihai O et al. A novel miniature cell retainer for correlative high-content analysis of individual untethered non-adherent cells. Laboratory Chip 2006; 6: 995-1000.
10. Deutsch A, Zurgil N, Hurevich I et al. Microplate cell-retaining methodology for high-content analysis of individual non-adherent unanchored cells in a population. Biomed Microdev 2006; 8: 361-74.
11. Deutsch M, Kaufman M, Shapiro H, Zurgil N. Analysis of enzyme kinetics in individual living cells utilizing fluorescence intensity and polarization measurements. Cytometry 2000; 39: 36-44.
12. Zurgil N, Sunray M, Shafran Y, Afrimzon E, Deutsch M. A novel approach for on line monitoring of apoptotic cell shrinkage in individual live lymphocytes. J Immunol Meth 2003; 281: 37-49.
13. Afrimzon E, Zurgil N, Shafran Y et al. Monitoring of intracellular enzyme kinetic characteristics of peripheral mononuclear cells in breast cancer patients. Cancer Epidemiol Biomarkers Prev 2004; 13: 235-41.
14. Sameni M, Dosescu J, Sloane BF. Imaging proteolysis by living human glioma cells. Biol Chem 2001; 382: 785-8.
15. Sameni M, Moin K, Sloarne BF. Imaging proteolysis by living human breast cancer cells. Neoplasia 2000; 2: 496-504.
16. Ludwig T. Local proteolytic activity in tumor cell invasion and metastasis. Bioassays 2005; 27: 1181-91.
17. Afrimzon E, Deutsch A, Shafran Y et al. Intracellular esterase activity in living cells may distinguish between metastatic and tumor-free lymph nodes. Clin Exp Metastasis 2008; Jan. 16 [Epub ahead of print.].
18. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-53.
19. Scoggins CR, Chagpar AB, Martin RCG, McMasters KM. Should sentinel lymph-node biopsy be used routinely for staging melanoma and breast cancers? Nat Clin Pract Oncol 2005; 2: 448-55.
20. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003; 83: 337-76.
21. Qian CN, Berghuis B, Tsarfaty G et al. Preparing the 'Soil': The primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res 2006; 66: 10.365-76.
22. Prutki M, Poljak-Blazi M, Jakopovic M, Tomas D, Stipancic I, Zarkovic N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett 2006; 238: 188-96.
23. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005; 2: E284.
24. Knutson KL, Krco CJ, Erskine CL et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006; 24: 4254-61.
25. Copier J, Ward S, Dalgleish A. Cell based cancer vaccines: Regulatory and commercial development. Vaccine 2007; 25 (Suppl 2): B35-46.
26. Ullman KS, Northrop JP, Verweij CL, Crabtree GR. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: The missing link. Annu Rev Immunol 1990; 8: 421-52.
27. Beverley PC. Activation antigens: New and previously defined clusters. In: McMichael AJ, ed. Leucocyte Typing III. Oxford: Oxford University Press, 1987; 516-28.
28. Barrett AJ, Rezvani K, Solomon S et al. New developments in allotransplant immunology. In: Hematology American Society of Hematology Education Program Book. San Francisco: The American Society of Hematology, 2003, 1, pp. 350-71.
29. Abraham M, Shapiro S, Karni A, Weiner HL, Miller A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs Th2 cells. J Neuroimmunol 2005; 163: 157-64.
30. Melamed D, Messika O, Glass-Marmor L, Miller A. Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis. Int Immunol 2006; 18: 1355-62.
31. Trocme C, Gaudin P, Berthier S, Barro C, Zaoui P, Morel F. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. J Biol Chem 1998; 273: 20.677-84.
32. Di Girolamo N, Tedla N, Lloyd A, Wakefield D. Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. Eur J Immunol 1998; 28: 1773-84.
33. Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 2001; 61: 3493-500.
34. Li HC, Cao DC, Liu Y et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004; 88: 75-85.